Amifostine in High-Dose Chemotherapy
Author Information
Author(s): Hartmann J T, Vangerow A von, Fels L M, Knop S, Stolte H, Kanz L, Bokemeyer C
Primary Institution: Dept. of Hematology and Oncology, UKT-Medical Center II, Eberhard-Karls-University of Tübingen
Hypothesis
Can amifostine reduce side effects during high-dose chemotherapy and improve patient outcomes?
Conclusion
Amifostine treatment during high-dose chemotherapy significantly reduced toxicity and hospital costs.
Supporting Evidence
- Amifostine-treated patients had a less pronounced increase in urinary protein excretion.
- Stomatitis grade III/IV occurred in 25% of control patients versus 0% in the amifostine group.
- Patients in the amifostine arm had a shorter duration of hospital stay.
Takeaway
This study found that a medicine called amifostine can help make chemotherapy less harmful and save money on hospital care.
Methodology
40 patients were randomized to receive high-dose chemotherapy with or without amifostine, and various side effects and costs were monitored.
Limitations
The study is a pilot with a small sample size and may not be generalizable.
Participant Demographics
Patients had solid tumors and were undergoing high-dose chemotherapy.
Statistical Information
P-Value
p = 0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website